Alzamend Neuro is trading at $1.49, a -5.70% change, and appears to be driven by extended-hours trading pressure after the August 17 close of $1.58.
- No clear company-specific catalyst or overnight announcement has been identified.
- Recent coverage remains focused on the previously announced $7.5 million financing; the company’s news page shows no newer major release.
- Volume data is unavailable.